Trial · NCT05323656
Adverse events168
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 168
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Erythema | Skin and subcutaneous tissue disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 0 | 27 | 0 |
| other | Erythema | Skin and subcutaneous tissue disorders | Placebo and Pembrolizumab 200 mg | 2 | 28 | 4 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 7 | 27 | 7 |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo and Pembrolizumab 200 mg | 6 | 28 | 8 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 | 27 | 3 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo and Pembrolizumab 200 mg | 2 | 28 | 3 |
| other | Dysphonia | Respiratory, thoracic and mediastinal disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 1 | 27 | 1 |
| other | Dysphonia | Respiratory, thoracic and mediastinal disorders | Placebo and Pembrolizumab 200 mg | 2 | 28 | 2 |
| other | Decreased appetite | Metabolism and nutrition disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 4 | 27 | 4 |
| other | Decreased appetite | Metabolism and nutrition disorders | Placebo and Pembrolizumab 200 mg | 6 | 28 | 11 |
| other | Hypokalaemia | Metabolism and nutrition disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 | 27 | 6 |
| other | Hypokalaemia | Metabolism and nutrition disorders | Placebo and Pembrolizumab 200 mg | 3 | 28 | 3 |
| other | Hypercalcaemia | Metabolism and nutrition disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 1 | 27 | 1 |
| other | Hypercalcaemia | Metabolism and nutrition disorders | Placebo and Pembrolizumab 200 mg | 3 | 28 | 4 |
| other | Hypermagnesaemia | Metabolism and nutrition disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 | 27 | 3 |
| other | Hypermagnesaemia | Metabolism and nutrition disorders | Placebo and Pembrolizumab 200 mg | 0 | 28 | 0 |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 0 | 27 | 0 |
| other | Hyperglycaemia | Metabolism and nutrition disorders | Placebo and Pembrolizumab 200 mg | 2 | 28 | 2 |
| other | Hyponatraemia | Metabolism and nutrition disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 0 | 27 | 0 |
| other | Hyponatraemia | Metabolism and nutrition disorders | Placebo and Pembrolizumab 200 mg | 2 | 28 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05323656/events?page=3